Janus Henderson Group PLC boosted its holdings in CorVel Co. (NASDAQ:CRVL - Free Report) by 230.2% in the fourth quarter, according to its most recent disclosure with the Securities & Exchange Commission. The institutional investor owned 136,908 shares of the business services provider's stock after purchasing an additional 95,445 shares during the quarter. Janus Henderson Group PLC owned about 0.27% of CorVel worth $15,233,000 as of its most recent SEC filing.
Several other hedge funds also recently added to or reduced their stakes in the stock. Barclays PLC grew its position in CorVel by 380.8% in the 3rd quarter. Barclays PLC now owns 15,977 shares of the business services provider's stock valued at $5,223,000 after buying an additional 12,654 shares during the last quarter. Franklin Resources Inc. boosted its holdings in CorVel by 9.9% during the third quarter. Franklin Resources Inc. now owns 1,917 shares of the business services provider's stock worth $614,000 after buying an additional 173 shares in the last quarter. Ellsworth Advisors LLC increased its holdings in CorVel by 210.6% in the fourth quarter. Ellsworth Advisors LLC now owns 7,269 shares of the business services provider's stock valued at $809,000 after buying an additional 4,929 shares in the last quarter. Ballentine Partners LLC lifted its position in shares of CorVel by 211.0% during the 4th quarter. Ballentine Partners LLC now owns 2,429 shares of the business services provider's stock valued at $270,000 after acquiring an additional 1,648 shares during the period. Finally, Nisa Investment Advisors LLC increased its stake in CorVel by 217.1% in the 4th quarter. Nisa Investment Advisors LLC now owns 555 shares of the business services provider's stock valued at $62,000 after purchasing an additional 380 shares in the last quarter. 51.36% of the stock is currently owned by hedge funds and other institutional investors.
Insider Buying and Selling at CorVel
In other news, Director Jeffrey J. Michael sold 16,523 shares of the stock in a transaction dated Wednesday, April 9th. The stock was sold at an average price of $116.99, for a total value of $1,933,025.77. Following the completion of the sale, the director now owns 551,787 shares in the company, valued at approximately $64,553,561.13. This trade represents a 2.91% decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this link. 47.57% of the stock is owned by company insiders.
Analyst Ratings Changes
Separately, Wall Street Zen upgraded CorVel from a "hold" rating to a "buy" rating in a research report on Friday, April 18th.
Read Our Latest Report on CRVL
CorVel Price Performance
Shares of NASDAQ CRVL traded up $4.47 on Thursday, hitting $116.77. The company's stock had a trading volume of 22,828 shares, compared to its average volume of 119,606. CorVel Co. has a 12-month low of $76.53 and a 12-month high of $128.61. The stock has a 50 day moving average of $111.72 and a 200-day moving average of $116.61. The company has a market capitalization of $6.00 billion, a price-to-earnings ratio of 68.60 and a beta of 1.10.
CorVel (NASDAQ:CRVL - Get Free Report) last issued its quarterly earnings results on Thursday, May 22nd. The business services provider reported $0.51 EPS for the quarter. CorVel had a net margin of 10.12% and a return on equity of 32.22%.
CorVel Company Profile
(
Free Report)
CorVel Corporation provides workers' compensation, auto, liability, and health solutions. It applies technology, including artificial intelligence, machine learning, and natural language processing to enhance the managing of episodes of care and the related health care costs. The company also offers network solutions services, including automated medical fee auditing, preferred provider management and reimbursement, retrospective utilization review, facility claim review, professional review, pharmacy, directed care, clearinghouse, independent medical examination, and inpatient medical bill review services, as well as Medicare solutions.
Read More

Before you consider CorVel, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and CorVel wasn't on the list.
While CorVel currently has a Hold rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
MarketBeat's analysts have just released their top five short plays for June 2025. Learn which stocks have the most short interest and how to trade them. Enter your email address to see which companies made the list.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.